Stock listing
NASDAQ:ALKS Alkermes plc Stock
Home listing (NASDAQ) of Alkermes plc
Follow Alkermes plc into a list and get an email when it puts out news.
Share price · NASDAQ:ALKS
$44.94 USD -1.91 (-4.1%)
Close on Nov 20, 2026
- Day range
- $44.83 – $46.89 USDNov 20, 2026
- Volume
- 1.07M sharesNov 20, 2026
- Market cap
- $7.55B USDAt the close on Nov 20, 2026 · price × 168.0M shares outstanding
- 52-week range
- $27.00 – $55.67 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $82.79M USDMedian day 1.64M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALKS · Home | $44.94 USD | -1.91 (-4.1%) | 1,070,769 | $45.79 | $46.89 | $44.83 | $46.85 | Close on Nov 20, 2026 |
| Frankfurt:8AK | €41.48 EUR | -0.18 (-0.4%) | — | €40.54 | €41.48 | €40.54 | €41.66 | Close on Nov 20, 2026 |
| Munich:8AK | €41.51 EUR | -1.48 (-3.4%) | — | €41.96 | €41.96 | €41.51 | €42.99 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALKS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $44.94 | -1.91 | -4.1% | $45.79 | $46.89 | $44.83 | 1,070,769 | |
| $46.85 | +1.40 | +3.1% | $45.26 | $47.06 | $45.25 | 1,394,840 | |
| $45.45 | -1.08 | -2.3% | $46.37 | $46.65 | $45.10 | 932,614 | |
| $46.53 | -0.50 | -1.1% | $47.02 | $47.76 | $46.26 | 1,051,956 | |
| $47.03 | +0.05 | +0.1% | $46.83 | $47.44 | $46.10 | 1,429,845 | |
| $46.98 | -0.91 | -1.9% | $46.00 | $48.30 | $45.27 | 3,125,379 | |
| $47.89 | +1.42 | +3.1% | $46.47 | $48.00 | $46.08 | 1,031,712 | |
| $46.47 | +0.30 | +0.6% | $45.67 | $46.57 | $45.35 | 1,035,989 | |
| $46.17 | +0.27 | +0.6% | $45.96 | $47.07 | $45.65 | 1,708,119 | |
| $45.90 | +1.36 | +3.1% | $44.19 | $45.94 | $44.07 | 1,650,400 | |
| $44.54 | -1.35 | -2.9% | $45.96 | $46.55 | $44.42 | 1,943,981 | |
| $45.89 | +0.20 | +0.4% | $46.23 | $47.01 | $44.58 | 2,164,906 | |
| $45.69 | +0.80 | +1.8% | $46.17 | $47.43 | $45.22 | 2,328,578 | |
| $44.89 | -0.45 | -1.0% | $45.59 | $45.92 | $44.49 | 2,155,778 | |
| $45.34 | -0.03 | -0.1% | $46.05 | $46.35 | $44.78 | 1,103,100 | |
| $45.37 | +0.12 | +0.3% | $46.01 | $46.38 | $45.18 | 1,424,102 | |
| $45.25 | +0.93 | +2.1% | $43.66 | $45.29 | $43.45 | 1,439,609 | |
| $44.32 | -0.12 | -0.3% | $44.34 | $45.02 | $43.99 | 1,322,006 | |
| $44.44 | +0.81 | +1.9% | $44.11 | $44.84 | $43.60 | 1,176,591 | |
| $43.63 | -0.55 | -1.2% | $44.15 | $44.15 | $43.15 | 884,392 | |
| $44.18 | +0.70 | +1.6% | $44.00 | $44.68 | $43.46 | 1,833,975 | |
| $43.48 | -0.63 | -1.4% | $44.12 | $44.58 | $43.44 | 1,781,814 | |
| $44.11 | +1.14 | +2.7% | $43.38 | $45.19 | $43.21 | 2,154,017 | |
| $42.97 | +1.75 | +4.2% | $41.46 | $43.64 | $41.35 | 2,713,432 | |
| $41.22 | +1.12 | +2.8% | $40.18 | $41.57 | $39.71 | 3,408,302 | |
| $40.10 | +1.02 | +2.6% | $39.74 | $40.74 | $39.42 | 1,976,642 | |
| $39.08 | -0.65 | -1.6% | $39.59 | $40.65 | $38.98 | 1,551,180 | |
| $39.73 | -0.53 | -1.3% | $40.26 | $40.35 | $39.67 | 1,068,300 | |
| $40.26 | -0.35 | -0.9% | $40.67 | $40.87 | $40.00 | 2,240,200 | |
| $40.61 | +0.50 | +1.2% | $40.18 | $40.87 | $39.99 | 1,627,000 | |
| $40.11 | -1.34 | -3.2% | $41.10 | $41.26 | $39.11 | 3,251,000 | |
| $41.45 | -0.20 | -0.5% | $41.28 | $42.06 | $41.17 | 1,816,000 | |
| $41.65 | -1.11 | -2.6% | $42.64 | $42.71 | $41.24 | 1,546,000 | |
| $42.76 | +1.01 | +2.4% | $42.07 | $43.22 | $41.67 | 3,125,200 | |
| $41.75 | +1.21 | +3.0% | $41.03 | $41.96 | $40.32 | 2,423,500 | |
| $40.54 | +0.02 | 0.0% | $40.00 | $41.41 | $39.99 | 2,625,700 | |
| $40.52 | -0.28 | -0.7% | $40.94 | $40.94 | $39.92 | 2,527,200 | |
| $40.80 | +0.65 | +1.6% | $39.84 | $40.90 | $39.84 | 2,686,800 | |
| $40.15 | -0.70 | -1.7% | $40.71 | $40.97 | $40.04 | 2,356,200 | |
| $40.85 | +0.06 | +0.1% | $40.94 | $41.12 | $40.49 | 2,588,000 | |
| $40.79 | -1.34 | -3.2% | $42.55 | $42.55 | $40.59 | 2,843,400 | |
| $42.13 | -1.16 | -2.7% | $43.20 | $43.62 | $41.23 | 2,475,700 | |
| $43.29 | -0.89 | -2.0% | $44.39 | $44.53 | $43.08 | 2,310,700 | |
| $44.18 | +0.79 | +1.8% | $44.27 | $44.79 | $43.11 | 3,731,100 | |
| $43.39 | -3.32 | -7.1% | $46.51 | $46.53 | $43.27 | 6,935,802 | |
| $46.71 | +0.64 | +1.4% | $47.10 | $47.40 | $46.41 | 1,423,600 | |
| $46.07 | +0.04 | +0.1% | $46.64 | $47.26 | $45.79 | 1,854,600 | |
| $46.03 | +0.20 | +0.4% | $45.73 | $46.14 | $44.63 | 2,151,200 | |
| $45.83 | -0.14 | -0.3% | $46.60 | $46.60 | $45.66 | 2,029,500 | |
| $45.97 | -0.14 | -0.3% | $46.75 | $46.75 | $45.73 | 1,283,100 | |
| $46.11 | +0.71 | +1.6% | $44.98 | $46.11 | $44.75 | 1,193,900 | |
| $45.40 | -0.09 | -0.2% | $45.24 | $45.61 | $44.72 | 1,442,800 | |
| $45.49 | -0.61 | -1.3% | $45.20 | $46.53 | $44.63 | 1,355,800 | |
| $46.10 | -0.78 | -1.7% | $46.14 | $46.93 | $45.80 | 1,064,000 | |
| $46.88 | -0.84 | -1.8% | $48.01 | $48.29 | $46.71 | 974,500 | |
| $47.72 | +0.52 | +1.1% | $47.70 | $48.74 | $46.68 | 1,566,400 | |
| $47.20 | +0.21 | +0.4% | $47.00 | $47.34 | $46.65 | 1,351,300 | |
| $46.99 | -0.42 | -0.9% | $47.25 | $47.56 | $46.46 | 1,440,900 | |
| $47.41 | -1.49 | -3.0% | $48.82 | $48.82 | $47.25 | 1,429,200 | |
| $48.90 | -0.26 | -0.5% | $48.72 | $49.33 | $48.10 | 2,119,400 | |
| $49.16 | -0.05 | -0.1% | $49.23 | $49.35 | $48.46 | 660,900 | |
| $49.21 | +0.34 | +0.7% | $48.94 | $49.58 | $48.87 | 1,127,442 | |
| $48.87 | +0.54 | +1.1% | $48.05 | $49.03 | $47.64 | 1,296,669 | |
| $48.33 | +0.31 | +0.6% | $48.05 | $48.67 | $47.33 | 939,600 | |
| $48.02 | -2.16 | -4.3% | $49.37 | $49.86 | $47.93 | 1,635,200 |
Splits
1 split · NASDAQ:ALKS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- NASDAQ:ALKS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Latest earnings call · Nov 3, 2026
Alkermes (NASDAQ:ALKS) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 16 slides
Latest news
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Nov 5, 2026
Closed $44.54 (-2.9%) on Nov 5, 2026
Alkermes to Present at Upcoming Investor Conferences
Nov 3, 2026
Closed $45.89 (+0.4%) on Nov 4, 2026
Alkermes plc Reports Third Quarter 2026 Financial Results
Nov 3, 2026
Closed $45.69 (+1.8%) on Nov 3, 2026
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Oct 30, 2026
Closed $45.34 (-0.1%) on Oct 30, 2026
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Oct 20, 2026
Closed $43.48 (-1.4%) on Oct 21, 2026
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Oct 13, 2026
Closed $39.73 (-1.3%) on Oct 13, 2026
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Sep 21, 2026
Closed $44.18 (+1.8%) on Sep 21, 2026
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Sep 16, 2026
Closed $46.07 (+0.1%) on Sep 16, 2026
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Sep 10, 2026
Closed $46.11 (+1.6%) on Sep 10, 2026
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Aug 24, 2026
Closed $49.21 (+0.7%) on Aug 25, 2026
Alkermes plc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 251 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 3, 2026
- Decks
- 73 decks · latest Nov 3, 2026
Where Alkermes plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALKS · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A1JKVH | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1JKVH | Lang & Schwarz | Germany | EUR |
| BOATS:ALKS | BOATS | United States | USD |
| Frankfurt:8AK | Frankfurt | Germany | EUR |
| Tradegate:8AK | Tradegate | Germany | EUR |
| Munich:8AK | Munich | Germany | EUR |
| Stuttgart:8AK | Stuttgart | Germany | EUR |
| Xetra:8AK | Xetra | Germany | EUR |
| Dusseldorf:8AK | Dusseldorf | Germany | EUR |
Valuation
EV/sales 4.7× against a median of 34.9×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $8.31B USD
- P/E
- Loss
- EV/sales
- 4.7×
- EV/EBITDA
- 57.3×
- Price/book
- 4.0×
- Gross margin
- 82.9%
- Operating margin
- 3.7%
- Net margin
- −0.0%
- Debt to equity
- 0.8×
- Beta vs S&P 500
- 0.80
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alkermes plc · NASDAQ:ALKS | US$7.55B | US$8.31B | n/a | 4.7× | 57.3× | 4.0× | −0.0% | 0.8× | 0.80 |
| Vaxcyte, Inc. · NASDAQ:PCVX | US$8.77B | US$7.70B | n/a | n/a | n/a | 3.5× | n/a | 0.1× | 1.24 |
| Praxis Precision Medicines, Inc. · NASDAQ:PRAX | US$8.40B | US$7.65B | n/a | n/a | n/a | 6.7× | n/a | 0.0× | 1.45 |
| Summit Therapeutics Inc. · NASDAQ:SMMT | US$7.96B | US$7.33B | n/a | n/a | n/a | 14.1× | n/a | 0.0× | 1.91 |
| Protagonist Therapeutics, Inc. · NASDAQ:PTGX | US$7.92B | US$7.13B | 23.1× | 12.9× | 22.0× | 7.3× | 62.0% | 0.0× | 0.93 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| Median of the others | US$7.09B | US$6.52B | 23.1× | 34.9× | 22.0× | 7.2× | −27.3% | 0.0× | 1.24 |
Forecasts
12 strong buy · 3 buy · 4 hold · 1 sell · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 57.74 USD · Analysts' mean
- EPS, year to Dec 2026
- 1.55 · 4 analysts
- Revenue, year to Dec 2026
- 1.82B · 18 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Blair C. Jackson | Chief Executive Officer |
| Joshua Reed | Chief Financial Officer |
| Anne Giovanoni | Senior Vice President, Corporate Counsel and Secretary |
| David Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary |
| Jamie Constantine | Investor Relations |
| Sandy Coombs | Investor Relations |
| Bhaskar Rege | Senior Vice President, Discovery Medicine & Pharmaceutical Sciences |
| Craig Hopkinson | Executive Vice President, Research & Development and Chief Medical Officer |
| Declan O’Connor | Senior Vice President, Operations and Environment, Health and Safety (EHS) |
| Drew Sansone | Senior Vice President, Regulatory Affairs |
| James Schoener | Senior Vice President, Business Development and Alliance Management |
| Julie Lekstrom Himes | Senior Vice President, Clinical Development |
| Kanchan Relwani | Senior Vice President, Medical Affairs |
| Peter Norman | Senior Vice President, Policy, Government & Community Relations |
| Stephen Schiavo | Senior Vice President, Chief Human Resources Officer |
| Todd Nichols | Senior Vice President, Chief Commercial Officer |
| Tom Skoff | Senior Vice President, Chief Information Officer |
Board
| Director | Role |
|---|---|
| Richard F. Pops | Director |
| Shane M. Cooke | Chairperson |
| Andy Wilson | |
| Anne C. Whitaker | Director |
| Blair C. Jackson | Chief Executive Officer |
| Brian P. McKeon | Director |
| Cato T. Laurencin | Director |
| Christopher I. Wright M.D. | Director |
| Nancy L. Snyderman | Director |
| Nancy S. Lurker | Director |
| Richard B. Gaynor | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Alkermes (NASDAQ:ALKS) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q2 2026 Earnings Call | Tue, Jul 28, 2026 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q1 2026 Earnings Call | Tue, May 05, 2026 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q4 2026 Earnings Call | Wed, Feb 25, 2026 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q3 2025 Earnings Call | Tue, Oct 28, 2025 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q1 2025 Earnings Call | Thu, May 01, 2025 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q3 2024 Earnings Call | Thu, Oct 24, 2024 · 8:00 PM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q2 2024 Earnings Call | Wed, Jul 24, 2024 · 8:00 AM ET | Replay |
| Alkermes (NASDAQ:ALKS) Q1 2024 Earnings Call | Wed, May 01, 2024 · 8:00 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +1.8% |
| Q2 2026 | Jul 28, 2026 · Before open | −4.2% |
| Q1 2026 | May 5, 2026 · Before open | +6.1% |
| Q4 2025 | Feb 25, 2026 | −8.0% |
| Q3 2025 | Oct 28, 2025 · Before open | +4.3% |
| Q2 2025 | Jul 29, 2025 · Before open | +3.3% |
| Q1 2025 | May 1, 2025 · Before open | +6.3% |
| Q4 2024 | Feb 12, 2025 · Before open | +4.8% |
| Q3 2024 | Oct 24, 2024 · Before open | −3.6% |
| Q2 2024 | Jul 24, 2024 · Before open | +6.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 1, 2024 · Before open | −2.2% |
| Q4 2023 | Feb 15, 2024 · Before open | +16.3% |
| Q3 2023 | Oct 25, 2023 · Before open | −7.4% |
| Q2 2023 | Jul 26, 2023 · Before open | −2.6% |
| Q1 2023 | Apr 26, 2023 · Before open | −7.0% |
| Q4 2022 | Feb 16, 2023 · Before open | +4.4% |
| Q3 2022 | Nov 2, 2022 · Before open | +3.5% |
| Q2 2022 | Jul 27, 2022 · Before open | −5.3% |
| Q1 2022 | Apr 27, 2022 · Before open | +11.9% |
| Q4 2021 | Feb 16, 2022 · Before open | +14.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 16 slides | Nov 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 16 slides | Jul 28, 2026 |
| SLEEP 2026 | Conference | 19 slides | Jun 17, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 16 slides | May 5, 2026 |
| Q4 2026 Earnings Presentation | Earnings | 19 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 12, 2026 |
| Technical Presentation (November 2025) | Technical | 15 slides | Nov 12, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 16 slides | Oct 28, 2025 |
| Merger or Acquisition (October 2025) | Merger or acquisition | 13 slides | Oct 22, 2025 |
| Technical Presentation (September 2025) | Technical | 58 slides | Sep 8, 2025 |
Show 50 decks
This page holds 50 of 73 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.48B | 1.56B | 1.66B | 1.11B | 1.17B | 1.04B | 1.17B | 1.09B | 903.4M | 745.7M |
| Cost of revenue | 196.5M | 245.3M | 253.0M | 218.1M | 197.3M | 178.3M | 180.4M | 176.4M | 154.7M | 132.1M |
| Gross profit | 1.28B | 1.31B | 1.41B | 893.7M | 976.4M | 860.4M | 990.6M | 917.9M | 748.6M | 613.6M |
| Research and development | 324.0M | 245.3M | 270.8M | 272.7M | 290.9M | 394.6M | 512.8M | 425.4M | 412.9M | 387.1M |
| Selling, general and administrative | 701.5M | 645.2M | 689.8M | 590.8M | 549.6M | 538.8M | 599.4M | 526.4M | 421.6M | 374.1M |
| Operating income | 254.0M | 420.6M | 414.1M | -6.09M | 97.7M | -112.4M | -175.5M | -99.1M | -147.9M | -208.7M |
| Depreciation and amortization | 27.2M | 28.5M | 74.9M | 77.9M | 78.7M | 81.9M | 80.4M | 103.7M | 98.5M | 94.3M |
| EBITDA | 281.1M | 449.2M | 489.0M | 71.8M | 176.4M | -30.6M | -95.1M | 4.53M | -49.4M | -114.4M |
| Interest expense | 12.3M | 22.6M | 23.0M | 13.0M | 11.2M | 8.66M | 13.6M | 15.4M | 12.0M | 14.9M |
| Income before tax | 291.4M | 443.8M | 421.5M | -31.1M | 87.7M | -96.5M | -197.1M | -127.0M | -143.3M | -214.4M |
| Income tax | 49.8M | 71.6M | -97.6M | 2.02M | 11.3M | 14.3M | -436.0K | 12.3M | 14.7M | -5.94M |
| Net income | 241.7M | 367.1M | 355.8M | -158.3M | -48.2M | -110.9M | -196.6M | -139.3M | -157.9M | -208.4M |
| Earnings per share, basic | 1.47 | 2.22 | 2.14 | -0.97 | -0.30 | -0.70 | -1.25 | -0.90 | -1.03 | -1.38 |
| Earnings per share, diluted | 1.43 | 2.17 | 2.10 | -0.97 | -0.29 | -0.70 | -1.25 | -0.90 | -1.03 | -1.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 388.6M | 291.1M | 457.5M | 292.5M | 337.5M | 273.0M | 203.8M | 266.8M | 191.3M | 186.4M |
| Short-term investments | 199.6M | 460.5M | 316.0M | 316.0M | 198.8M | 362.1M | 331.2M | 272.5M | 242.2M | 310.9M |
| Receivables | 334.0M | 384.5M | 332.5M | 288.0M | 313.2M | 275.1M | 257.1M | 292.2M | 233.6M | 191.1M |
| Inventory | 196.6M | 182.9M | 186.4M | 181.4M | 150.3M | 125.7M | 101.8M | 90.2M | 93.3M | 63.0M |
| Current assets | 1.93B | 1.42B | 1.49B | 1.13B | 1.06B | 1.11B | 962.0M | 983.3M | 808.8M | 790.7M |
| Property, plant and equipment | 221.7M | 227.6M | 226.9M | 222.9M | 341.1M | 350.0M | 362.2M | 310.0M | 284.7M | 264.8M |
| Goodwill | 83.0M | 83.0M | 83.0M | 83.0M | 92.9M | 92.9M | 92.9M | 92.9M | 92.9M | 92.9M |
| Total assets | 2.49B | 2.06B | 2.14B | 1.96B | 2.02B | 1.95B | 1.81B | 1.83B | 1.80B | 1.73B |
| Accounts payable | 108.0M | 45.6M | 65.6M | 32.8M | 55.7M | 46.0M | 54.3M | 39.8M | 55.5M | 46.3M |
| Current liabilities | 543.4M | 465.2M | 520.2M | 497.7M | 471.3M | 438.3M | 391.1M | 339.8M | 291.1M | 212.0M |
| Long-term debt | 0 | 287.7M | 290.3M | 292.8M | 272.1M | 274.3M | 276.5M | 278.4M | 280.7M | |
| Total debt | 0 | 75.5M | 290.7M | 293.3M | 295.8M | 275.0M | 277.1M | 279.3M | 281.4M | 283.7M |
| Total liabilities | 667.7M | 590.6M | 933.5M | 920.2M | 911.9M | 882.7M | 720.0M | 653.7M | 594.4M | 516.9M |
| Shareholders' equity | 1.82B | 1.46B | 1.20B | 1.04B | 1.11B | 1.07B | 1.09B | 1.17B | 1.20B | 1.21B |
| Shares outstanding | 165.6M | 162.2M | 167.0M | 164.4M | 161.9M | 159.2M | 157.8M | 155.8M | 154.0M | 152.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 520.8M | 439.1M | 401.4M | 21.0M | 101.7M | 82.8M | 72.1M | 99.3M | 19.2M | -63.8M |
| Capital spending | -40.4M | -33.5M | -48.0M | -38.3M | -28.0M | -42.2M | -90.9M | -69.4M | -51.3M | -43.7M |
| Free cash flow | 480.3M | 405.6M | 353.3M | -17.2M | 73.7M | 40.6M | -18.9M | 29.9M | -32.1M | -107.5M |
| Cash from investing | 295.5M | -111.3M | 53.4M | -64.5M | -66.2M | -11.5M | -141.8M | -22.2M | -18.4M | 127.2M |
| Cash from financing | 12.4M | -494.1M | -289.7M | -1.57M | 29.1M | -2.17M | 6.76M | -1.62M | 4.08M | -58.2M |
| Dividends paid | -1.43M | -8.75M | -672.0K | -9.61M | 0 | 0 | ||||
| Share buybacks | -31.0M | -200.3M | -28.5M | -18.2M | -16.6M | -7.70M | -9.32M | -19.6M | -16.4M | -13.5M |
| Change in cash | 828.6M | -166.3M | 165.0M | -45.1M | 64.6M | 69.2M | -63.0M | 75.5M | 4.92M | 5.27M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Material contract | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Sep 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 3, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jul 28, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2026 | Results | SEC |
| 8-K · Current report | Jul 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 22, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 20, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | May 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 12, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 8-K/A · Current report, amended | May 1, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 6, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 28, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2025 | Results | SEC |
| 8-K · Current report | Oct 22, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 12, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jul 29, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2025 | Results | SEC |
| 8-K · Current report | Jul 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 21, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | May 12, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 7, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 7, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Alkermes plc’s releases
- Common shares
- 168,043,540
- Fully diluted
- 168,043,540
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 168,043,540 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 168,043,540 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Wendy L Dixon Other companies: Zevra Therapeutics, Inc. (Director · Since at least Apr 25, 2023); Iovance Biotherapeutics, Inc. (Director · Jun 10, 2022 – Jun 10, 2022 · Past); Black Diamond Therapeutics, Inc. (Director · Apr 6, 2022 – Mar 15, 2024 · Past); Arvinas, Inc. (Director · Jun 29, 2020 – Jun 15, 2023 · Past); Sesen Bio Inc (Director · Jun 12, 2018 – Jun 19, 2019 · Past); Voyager Therapeutics, Inc. (Director · Jan 1, 2017 – Jun 4, 2020 · Past); Eleven Biotherapeutics Inc (Director · Oct 22, 2014 – May 19, 2017 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Nov 11, 2021 · Past); Ardea Biosciences Inc (Director · Apr 6, 2011 – Jun 19, 2012 · Past); Furiex Pharmaceuticals Inc (Director · May 27, 2010 – Jul 2, 2014 · Past); Incyte Corporation (Director · May 21, 2010 – Mar 31, 2022 · Past); Orexigen Therapeutics Inc (Director · Apr 20, 2010 – Jun 9, 2015 · Past); Dentsply Sirona Inc. (Director · Jul 31, 2007 – Jul 8, 2010 · Past); Bristol-Myers Squibb Company (CMO & Pres, Global Marketing · Mar 7, 2006 – May 22, 2006 · Past) | Director · Jan 13, 2011 – Jun 14, 2022 · Past |
| Paul Schimmel Other companies: aTyr Pharma, Inc. (Director · Since at least May 6, 2015); Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Repligen Corporation (Director · Aug 11, 2006 – Jun 14, 2007 · Past) | Director · Mar 2, 2006 – Jun 15, 2007 · Past |
| Frank A. Wilson Other companies: Novanta Inc. (Member of Board of Directors · Since at least May 13, 2021); Cabot Corporation (Director · Since at least Sep 13, 2018); Sparton Corporation (Director · Mar 4, 2019 – Mar 4, 2019 · Past); Revvity, Inc. (Please See Remarks · Dec 7, 2017 – Mar 5, 2018 · Past) | Director · Since at least Sep 12, 2019 |
| James A Robinson Jr Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Oct 1, 2023); UroGen Pharma Ltd. (Director · Since at least Jul 25, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past) | President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past |
| Joshua Reed Other companies: Scholar Rock Holding Corporation (Director · Since at least Mar 16, 2021); Omega Therapeutics Inc (Chief Financial Officer · May 23, 2022 – Feb 7, 2024 · Past); Aldeyra Therapeutics, Inc. (Chief Financial Officer · Jul 30, 2018 – Mar 30, 2022 · Past) | SVP, Chief Financial Officer · Since at least Sep 12, 2025 |
| Nancy L. Snyderman Other companies: Lyra Therapeutics, Inc. (Board Director · Since at least Oct 27, 2020); Future Health Esg Corp (Director · Sep 9, 2021 – Oct 24, 2021 · Past); Axonics Modulation Technologies Inc (Director · Apr 8, 2019 – Aug 24, 2020 · Past) | Director · Since at least May 23, 2018 |
| Nancy S. Lurker Other companies: Collegium Pharmaceutical, Inc. (Director · Since at least Feb 4, 2025); EyePoint, Inc. (Director · Since at least Mar 29, 2019); Aquestive Therapeutics, Inc. (Director · Jun 13, 2019 – Jun 15, 2021 · Past) | Director · Since at least Mar 5, 2024 |
| Richard F. Pops Other companies: Neurocrine Biosciences, Inc. (Director · Since at least May 28, 2015); Acceleron Pharma Inc (Director · Mar 3, 2016 – Jan 25, 2019 · Past); Epizyme Inc (Director · Jul 8, 2015 – May 29, 2020 · Past) | Director · Since at least Sep 10, 2015 |
| James M. Frates Other companies: Amylyx Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jan 6, 2022); Sage Therapeutics Inc (Director · Since at least Jul 17, 2014) | SVP, Alks Inc; CFO ALKS · May 2, 2006 – May 14, 2020 · Past |
| Shane M. Cooke Other companies: Prothena Corporation plc (Director · Since at least May 16, 2018); Endo International PLC (Director · Jun 8, 2018 – Jun 11, 2021 · Past) | Director · Since at least Jan 11, 2018 |
All 40 people
| Person | Seat |
|---|---|
| Brian P. McKeon Other companies: Dentsply Sirona Inc. (Director · Since at least Feb 24, 2026) | Director · Since at least Aug 18, 2025 |
| Craig Hopkinson Other companies: Albireo Pharma Inc (Director · Dec 1, 2022 – Mar 2, 2023 · Past) | Executive Vice President, Research & Development and Chief Medical Officer · Since at least Jun 7, 2019 |
| Emily Peterson Alva Other companies: Amneal Pharmaceuticals, Inc. (Director · May 4, 2018 – May 5, 2025 · Past) | Director · May 18, 2021 – Jun 29, 2024 · Past |
| Michael J Landine Other companies: Kopin Corporation (Director · May 11, 2012 – May 9, 2018 · Past) | SVP, Corp Dev., Alkermes, Inc. · Oct 3, 2011 – Feb 23, 2024 · Past |
| Richard B. Gaynor Other companies: Zai Lab Ltd. (Director · Since at least Nov 19, 2021) | Director · Since at least Dec 2, 2020 |
| Andy Wilson | Director · Since at least Feb 25, 2026 |
| Anne C. Whitaker | Director · Since at least Sep 16, 2026 |
| Anne Giovanoni | Senior Vice President, Corporate Counsel and Secretary · Since at least Nov 5, 2026 |
| Bhaskar Rege | Senior Vice President, Discovery Medicine & Pharmaceutical Sciences · Since at least Nov 5, 2026 |
| Blair Jackson | Chief Executive Officer · Since at least Jan 11, 2021 |
| Cato T. Laurencin | Director · Since at least May 21, 2026 |
| Christopher I. Wright M.D. | Director · Since at least May 21, 2026 |
| David Angelo Daglio Jr | Director · Dec 9, 2020 – Jun 29, 2024 · Past |
| David Gaffin | EVP, CLO, Alkermes, Inc. · Since at least Feb 16, 2021 |
| Declan O’Connor | Senior Vice President, Operations and Environment, Health and Safety (EHS) · Since at least Nov 5, 2026 |
| Drew Sansone | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Elliot Ehrich | EVP, R&D & CMO, Alkermes, Inc. · May 17, 2010 – May 28, 2017 · Past |
| Gordon G Pugh | SVP, COO & CRO, Alkermes, Inc. · Sep 21, 2006 – Dec 31, 2016 · Past |
| James Schoener | Senior Vice President, Business Development and Alliance Management · Since at least Nov 5, 2026 |
| Jamie Constantine | Investor Relations · Since at least Jul 14, 2026 |
| Julie Lekstrom Himes | Senior Vice President, Clinical Development · Since at least Oct 13, 2026 |
| Kanchan Relwani | Senior Vice President, Medical Affairs · Since at least Apr 30, 2025 |
| Paul J Mitchell | Director · Sep 21, 2006 – May 20, 2021 · Past |
| Peter Norman | Senior Vice President, Policy, Government & Community Relations · Since at least Nov 5, 2026 |
| Robert A Breyer | Director · Oct 5, 2011 – May 20, 2021 · Past |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) · Since at least May 29, 2026 |
| Sandy Coombs | Investor Relations · Since at least Apr 21, 2026 |
| Stephen Schiavo | Senior Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Todd Nichols | Senior Vice President, Chief Commercial Officer · Since at least Nov 5, 2026 |
| Tom Skoff | Senior Vice President, Chief Information Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Alkermes plc.